Ansa Biotechnologies’ CEO Daniel Lin-Arlow’s passion is helping scientists do their job faster and deliver their innovation to the world. His latest solution? Enzymatic DNA synthesis. DNA writing is ...
Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA constructs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results